Table 4.

Multivariable association of survival with metformin use (timing initiation and intensity) or statin use (timing initiation, name, type, potency, and intensity) among prediagnosis users

CharacteristicsNo. of users vs. nonusersAdjusted HR (95% CI)P
Timing of metformin initiation
 ≤6 months before diagnosis497/9,1771.06 (0.96–1.16)b0.27
 >6 months before diagnosis2,613/9,1771.04 (0.99–1.09)b0.17
Metformin intensity
 <1,000 mg/day700/9,1771.00 (0.92–1.08)b0.93
 1,000–1,500 mg/day1,297/9,1771.10 (1.03–1.17)b<0.01
 >1,500 mg/day1,113/9,1771.00 (0.94–1.07)b0.97
Timing of statin initiation
 ≤6 months before diagnosis411/5,6210.96 (0.87–1.07)c0.47
 >6 months before diagnosis6,422/5,6210.95 (0.91–0.98)c<0.01
Statin namea
 Atorvastatin2,127/5,6210.97 (0.92–1.02)c0.22
 Fluvastatin85/5,6211.26 (1.00–1.59)c0.05
 Lovastatin1,490/5,6210.98 (0.92–1.04)c0.46
 Pravastatin732/5,6210.93 (0.86–1.01)c0.07
 Rosuvastatin561/5,6210.88 (0.81–0.96)c<0.01
 Simvastatin3,794/5,6210.98 (0.94–1.02)c0.30
Statin typea
 Lipophilic6,184/5,6210.96 (0.92–1.00)c0.05
 Hydrophilic1,236/5,6210.91 (0.86–0.97)c<0.01
Statin potencya
 Low2,230/5,6210.98 (0.93–1.03)c0.41
 High5,544/5,6210.95 (0.91–0.99)c<0.01
Statin intensity
 Low1,817/5,6210.92 (0.87–0.98)c<0.01
 Moderate2,633/5,6210.95 (0.90–1.00)c0.04
 High2,383/5,6210.96 (0.92–1.01)c0.15
  • aCategories are not mutually exclusive for these variables.

  • bAdjusted for tumor characteristics: stage, grade, tumor size, treatment: resection, radiation, chemotherapy, propensity score for metformin use, and statin use (time-dependent variable).

  • cAdjusted for tumor characteristics: stage, grade, tumor size, treatment: resection, radiation, chemotherapy, propensity score for statin use, and metformin use (time-dependent variable).